Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove

  1. Curtis McMurtrey
  2. Thomas Trolle
  3. Tiffany Sansom
  4. Soumya G Remesh
  5. Thomas Kaever
  6. Wilfried Bardet
  7. Kenneth Jackson
  8. Morten Nielsen
  9. Rima McLeod
  10. Dirk M Zajonc
  11. Ira J Blader
  12. Bjoern Peters
  13. Alessandro Sette
  14. William Hildebrand  Is a corresponding author
  1. University of Oklahoma Health Sciences Center, United States
  2. Technical University of Denmark, Denmark
  3. University at Buffalo School of Medicine, United States
  4. La Jolla Institute for Allergy and Immunology, United States
  5. University of Chicago, United States
  6. University of Oklahoma Health Science Center, United States

Abstract

HLA class I presentation of pathogen-derived peptide ligands is essential for CD8+ T-cell recognition of Toxoplasma gondii infected cells. Currently, little data exist pertaining to peptides that are presented after T. gondii infection. Herein we purify HLA-A*02:01 complexes from T. gondii infected cells and characterize the peptide ligands using LCMS. We identify 195 T. gondii encoded ligands originating from both secreted and cytoplasmic proteins. Surprisingly, T. gondii ligands are significantly longer than uninfected host ligands, and these longer pathogen-derived peptides maintain a canonical N-terminal binding core yet exhibit a C-terminal extension of 1-30 amino acids. Structural analysis demonstrates that binding of extended peptides opens the HLA class I F' pocket, allowing the C-terminal extension to protrude through one end of the binding groove. In summary, we demonstrate that unrealized structural flexibility makes MHC class I receptive to parasite-derived ligands that exhibit unique C-terminal peptide extensions.

Article and author information

Author details

  1. Curtis McMurtrey

    Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Thomas Trolle

    Center for Biological Sequence Analysis, Technical University of Denmark, Kongens Lyngby, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  3. Tiffany Sansom

    Department of Microbiology and Immunology, University at Buffalo School of Medicine, Buffalo, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Soumya G Remesh

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Thomas Kaever

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Wilfried Bardet

    Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Kenneth Jackson

    Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Morten Nielsen

    Center for Biological Sequence Analysis, Technical University of Denmark, Kongens Lyngby, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  9. Rima McLeod

    University of Chicago, Chicago, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Dirk M Zajonc

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Ira J Blader

    Department of Microbiology and Immunology, University at Buffalo School of Medicine, Buffalo, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Bjoern Peters

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Alessandro Sette

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. William Hildebrand

    Department of Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, United States
    For correspondence
    william-hildebrand@ouhsc.edu
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2016, McMurtrey et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,318
    views
  • 497
    downloads
  • 68
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Curtis McMurtrey
  2. Thomas Trolle
  3. Tiffany Sansom
  4. Soumya G Remesh
  5. Thomas Kaever
  6. Wilfried Bardet
  7. Kenneth Jackson
  8. Morten Nielsen
  9. Rima McLeod
  10. Dirk M Zajonc
  11. Ira J Blader
  12. Bjoern Peters
  13. Alessandro Sette
  14. William Hildebrand
(2016)
Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove
eLife 5:e12556.
https://doi.org/10.7554/eLife.12556

Share this article

https://doi.org/10.7554/eLife.12556

Further reading

    1. Immunology and Inflammation
    Yan Qian, Qiannv Liu ... Pengyan Xia
    Research Article

    The T6SS of Pseudomonas aeruginosa plays an essential role in the establishment of chronic infections. Inflammasome-mediated inflammatory cytokines are crucial for host defense against bacterial infections. We found that P. aeruginosa infection activates the non-canonical inflammasome in macrophages, yet it inhibits the downstream activation of the NLRP3 inflammasome. The VgrG2b of P. aeruginosa is recognized and cleaved by caspase-11, generating a free C-terminal fragment. The VgrG2b C-terminus can bind to NLRP3, inhibiting the activation of the NLRP3 inflammasome by rejecting NEK7 binding to NLRP3. Administration of a specific peptide that inhibits caspase-11 cleavage of VgrG2b significantly improves mouse survival during infection. Our discovery elucidates a mechanism by which P. aeruginosa inhibits host immune response, providing a new approach for the future clinical treatment of P. aeruginosa infections.

    1. Immunology and Inflammation
    2. Medicine
    Ole Bæk, Tik Muk ... Duc Ninh Nguyen
    Research Article

    Preterm infants are susceptible to neonatal sepsis, a syndrome of pro-inflammatory activity, organ damage, and altered metabolism following infection. Given the unique metabolic challenges and poor glucose regulatory capacity of preterm infants, their glucose intake during infection may have a high impact on the degree of metabolism dysregulation and organ damage. Using a preterm pig model of neonatal sepsis, we previously showed that a drastic restriction in glucose supply during infection protects against sepsis via suppression of glycolysis-induced inflammation, but results in severe hypoglycemia. Now we explored clinically relevant options for reducing glucose intake to decrease sepsis risk, without causing hypoglycemia and further explore the involvement of the liver in these protective effects. We found that a reduced glucose regime during infection increased survival via reduced pro-inflammatory response, while maintaining normoglycemia. Mechanistically, this intervention enhanced hepatic oxidative phosphorylation and possibly gluconeogenesis, and dampened both circulating and hepatic inflammation. However, switching from a high to a reduced glucose supply after the debut of clinical symptoms did not prevent sepsis, suggesting metabolic conditions at the start of infection are key in driving the outcome. Finally, an early therapy with purified human inter-alpha inhibitor protein, a liver-derived anti-inflammatory protein, partially reversed the effects of low parenteral glucose provision, likely by inhibiting neutrophil functions that mediate pathogen clearance. Our findings suggest a clinically relevant regime of reduced glucose supply for infected preterm infants could prevent or delay the development of sepsis in vulnerable neonates.